PubMed Health⌕ Search

PubMed · 7369183

Two new artifacts in automated coagulation testing.

Abstract

Two artifacts were noted during the routine use of the Sherwood Lancer Coagulyzer. The first was that prothrombin times for 44 patients were greater than 90 sec on the Sherwood instrument, but were significantly shorter using reference methods. All 44 patients had subnormal fibrinogen values. Continuous optical density tracings during clotting performed for 11 patients demonstrated low slopes and amplitudes. For the three patients tested, the addition of fibrinogen corrected prothrombin times to values similar to those obtained on the Bio-Data instrument. Twenty-four of the patients subsequently died, 20 within three weeks of the observation of the artifact. The second artifact was that activated partial thromboplastin times for 12 patients were 9 sec on the Sherwood instrument, but were either normal or prolonged when using reference methods. Continuous tracings performed for nine patients demonstrated early optical density increases before clotting, which were responsible for the spurious values. Eleven of the 12 patients were hypoalbuminemic, and nine of the ten tested had elevated IgM levels. For seven patients, the artifact disappeared with in-vitro correction of hypoalbuminemia. Far from being weaknesses of the Coagulyzer, these artifacts may lead to the discovery of unsuspected, clinically significant laboratory information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S I Gutman, P Didisheim, H Markowitz. 1980. Two new artifacts in automated coagulation testing.. https://doi.org/10.1093/ajcp%2F73.4.583

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.

In some mild haemophilia A patients (discrepant haemophilia), factor VIII coagulant activity (FVIII:C) levels, by one-stage assay are more than double than those by two-stage assay. This may be due to the longer incubation times (10-12 min) in the two-stage assay. This study aimed to determine the time course of the activation phase of the two-stage assay, using both classical coagulation and chromogenic detection methods. In both systems, for equivalent patients (equivalent FVIII:C levels by one-stage and two-stage assays, n = 6, all different mutations), similar FVIII:C results were obtained with short- or long-incubation times. In contrast, plasma from discrepant patients (n = 8, five different mutations) showed higher FVIII:C at shorter incubation times than after longer incubation times. In the chromogenic assay, FVIII:C levels were higher after incubation for 2 min (23-56%, mean 41%) than after 10 min (19-41%, mean 29%). In the classical coagulation assay, FVIII:C levels were higher at shorter incubation times (21-64%, mean 37%) than with the longer incubation times usually used (13-29%, mean 23%). These time-course experiments have verified that the longer incubation time used in the two-stage assay is at least partly responsible for the lower FVIII:C measured by that assay in discrepant haemophilia.

Blood Coagulation Tests↗

Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes.

In the treatment of haemophilia A and B, recombinant coagulation factors are increasingly replacing plasma-derived factor VIII and IX concentrates. Although provided with replacement therapy, individual patients may exhibit bleeding episodes, which are difficult to control. These bleeds may be caused by von Willebrand disease (VWD) as an additional underlying coagulation disorder. We report in the present study our experience that in the collective of haemophilic patients, VWD must be anticipated at least with the same order of magnitude as it appears in a normal healthy population. Among the patients at our treatment centre, two patients (1.5%) were identified as suffering from VWD in addition to haemophilia A. In the collective of haemophilia B patients at our centre, three patients (10%) with VWD were found. Two of these patients exhibited unexpected severe bleeding episodes, which could only satisfactorily be controlled by the administration of Haemate-P or DDAVP supplementary to the recombinant coagulation factor concentrate.

Blood Coagulation Tests↗